Literature DB >> 8955560

Psychopharmacology of prepulse inhibition in mice.

S C Dulawa1, M A Geyer.   

Abstract

The attenuation of the startle response termed "prepulse inhibition" (PPI) occurs when an abrupt startling stimulus is preceded 30-500 msec by a barely detectable prestimulus or "prepulse". PPI provides a measure of sensorimotor gating, which is a short time-constant central processing mechanism that is disrupted in patients with schizophrenia, and a number of other neuropsychiatric disorders. The present experiments examined normal PPI in the mouse, and assessed the effects of apomorphine, d-amphetamine, PCP, and MDMA on mouse PPI. As predicted, mice demonstrated robust and reliable PPI, and each compound tested disrupted PPI. As with rats, 2.0 mg/kg apomorphine, 10.0 mg/kg PCP, and 10.0 mg/kg MDMA disrupted PPI significantly, while 5.0 mg/kg d-amphetamine produced a large reduction of PPI that approached significance. Our findings suggest that the mouse may provide another model system for the study of sensorimotor gating mechanisms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8955560

Source DB:  PubMed          Journal:  Chin J Physiol        ISSN: 0304-4920            Impact factor:   1.764


  26 in total

1.  Effect of adrenalectomy and corticosterone replacement on prepulse inhibition and locomotor activity in mice.

Authors:  Maarten van den Buuse; Margaret Morris; Carolina Chavez; Sally Martin; JianHong Wang
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

2.  Integration of genome-wide association and extant brain expression QTL identifies candidate genes influencing prepulse inhibition in inbred F1 mice.

Authors:  L J Sittig; P Carbonetto; K A Engel; K S Krauss; A A Palmer
Journal:  Genes Brain Behav       Date:  2016-01-08       Impact factor: 3.449

3.  Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists.

Authors:  R J Ralph; M P Paulus; F Fumagalli; M G Caron; M A Geyer
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

Review 4.  Comprehensive neurocognitive endophenotyping strategies for mouse models of genetic disorders.

Authors:  Michael R Hunsaker
Journal:  Prog Neurobiol       Date:  2012-01-13       Impact factor: 11.685

5.  Modulation of prepulse inhibition and stereotypies in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists.

Authors:  Aude Burban; Chit Sadakhom; Dominique Dumoulin; Christiane Rose; Gwenaëlle Le Pen; Henriette Frances; Jean-Michel Arrang
Journal:  Psychopharmacology (Berl)       Date:  2010-05-01       Impact factor: 4.530

6.  RIM1alpha and interacting proteins involved in presynaptic plasticity mediate prepulse inhibition and additional behaviors linked to schizophrenia.

Authors:  Jacqueline Blundell; Pascal S Kaeser; Thomas C Südhof; Craig M Powell
Journal:  J Neurosci       Date:  2010-04-14       Impact factor: 6.167

7.  Selective activation of D1 dopamine receptors impairs sensorimotor gating in Long-Evans rats.

Authors:  Laura J Mosher; Roberto Frau; Alessandra Pardu; Romina Pes; Paola Devoto; Marco Bortolato
Journal:  Br J Pharmacol       Date:  2015-07-30       Impact factor: 8.739

8.  Age-associated improvements in cross-modal prepulse inhibition in mice.

Authors:  Jared W Young; Chelsea K Wallace; Mark A Geyer; Victoria B Risbrough
Journal:  Behav Neurosci       Date:  2010-02       Impact factor: 1.912

9.  Repetitive behavior profile and supersensitivity to amphetamine in the C58/J mouse model of autism.

Authors:  Sheryl S Moy; Natallia V Riddick; Viktoriya D Nikolova; Brian L Teng; Kara L Agster; Randal J Nonneman; Nancy B Young; Lorinda K Baker; Jessica J Nadler; James W Bodfish
Journal:  Behav Brain Res       Date:  2013-11-08       Impact factor: 3.332

10.  Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice.

Authors:  Suzanne A Brody; Mark A Geyer; Charles H Large
Journal:  Psychopharmacology (Berl)       Date:  2003-04-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.